Why CNS Pharmaceuticals Shares Are Trading Higher

CNS Pharmaceuticals Inc CNSP shares are trading higher by 15.47% to $1.00 after the company announced it received approval from the Competent Authority and the central Ethics Committee in Italy for its potentially pivotal global trial evaluating Berubicin for the treatment of GBM.

The company plans to open its clinical sites in Italy imminently in addition to the previously opened 41 clinical trial sites of the 60 sites selected across the U.S., France, Spain and Switzerland.

See Also: Why Tellurian Shares Are Surging Thursday

"Our team has continued to make dedicated efforts to build momentum and drive patient enrollment in this important clinical trial. We are incredibly pleased to add Italy to our growing portfolio of European countries for this global study," commented John Climaco, CEO of CNS Pharmaceuticals in part of a statement Thursday.

According to data from Benzinga Pro, CNSP has a 52-week high of $13.42 and a 52-week low of $0.85.